AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12399289
Drug: Purified isoflavone
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified isoflavone preparation (formulation A) with a genistein dose of 2, 4, 8, or 16 mg/kg body wt
Trial: 12399289
Drug: Purified isoflavone
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified isoflavone preparation (formulation A)
Trial: 7477218
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of lamivudine every 12 hours
Trial: 7477218
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of zidovudine every 8 hours
Trial: 7477218
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of lamivudine every 12 hours plus zidovudine
Trial: 7477218
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of lamivudine every 12 hours plus zidovudine
Trial: 2155751
Drug: 400 units
RxNorm normalized name: alpha-D-galactosidase 400 units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 units of intranasal calcitonin
Trial: 2155751
Drug: Subcutaneous calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcitonin (1, 10, 100 units)
Trial: 7250475
Drug: Aromatic retinoid
RxNorm normalized name: Curcuma aromatica root oil
DrugBank: Curcuma aromatica root oil (DB11301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic retinoid Ro 10-9359 (AR) combined with PUVA therapy (schedule C)
Trial: 7250475
Drug: PUVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA therapy alone
Trial: 30488331
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (abstinence)
Trial: 27692491
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - a handout on staying healthy during treatment
Trial: 19671089
Drug: Tramadol Contramid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol Contramid OAD 200 mg
Trial: 19671089
Drug: Tramadol Contramid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol Contramid OAD 300 mg
Trial: 16281465
Drug: Prophylactic laser
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic laser treatment to the retina
Trial: 31607823
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) sessions offered weekly (VRidays) and access to high-end VR stations in the Nexus Reality Lab.
Trial: 17629752
Drug: Age, surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, surgery type, platelets, body mass index, and length of time from surgery to chemotherapy
Trial: 17371885
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with tapered high-dose prednisone (group 3)
Trial: 17405834
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with infliximab (group 4)
Trial: 17405834
Drug: Sequential monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential monotherapy (group 1)
Trial: 18438829
Drug: Step-up combination
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up combination therapy (group 2)
Trial: 8201375
Drug: CYVADIC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYVADIC chemotherapy (cyclophosphamide 500 mg/m2 IV bolus on day 1, vincristine 1.4 mg/m2 IV bolus on day 1, doxorubicin 50 mg/m2 IV bolus on day 1, dacarbazine 400 mg/m2 by 1-hour infusion on days 1 to 3, repeated every 28 days for eight courses)
Trial: 8201375
Drug: CYVADIC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYVADIC chemotherapy
Trial: 3662061
Drug: midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.2 mg/kg
Trial: 3662061
Drug: thiopental 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiopental 3.5 mg/kg
Trial: 29549523
Drug: High cadence
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cadence (90 r/min) + taurine (50 mg/kg body mass)
Trial: 29549523
Drug: High cadence
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cadence (90 r/min) + placebo (3 mg/kg body mass maltodextrin)
Trial: 25867422
Drug: External rhGM‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External rhGM‐CSF gel
Trial: 25867422
Drug: rhGM‐CSF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF gel matrix components (Control)
Trial: 21036772
Drug: Once-daily regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily regimen of emtricitabine, didanosine and efavirenz
Trial: 21036772
Drug: Protease inhibitor‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor‐based regimen
Trial: 16553634
Drug: Adjunctive metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive metronidazole plus amoxicillin
Trial: 16553634
Drug: Adjunctive metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive metronidazole
Trial: 15292323
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of GH therapy (0.35 U/kg.wk)
Trial: 15292323
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of GH therapy
Trial: 3874643
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg‐1 over 5 s
Trial: 3874643
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg‐1 over 20 s
Trial: 3874643
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg kg‐1 over 60 s
Trial: 19487320
Drug: Gaboxadol (GBX)
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol (GBX) 5, 10, and 15 mg
Trial: 19487320
Drug: Zolpidem (ZOL)
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem (ZOL) 10 mg
Trial: 16680965
Drug: MEBO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEBO treatment
Trial: 16680965
Drug: SD-Ag cream
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-Ag cream treatment
Trial: 10986219
Drug: L-ornithine-L-aspartate (LOLA)
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine-L-aspartate (LOLA) 5 g intravenously
Trial: 9380238
Drug: Dialysis patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis patients with elevated plasma silicon levels (3,849 and 2,350 micrograms/l)
Trial: 31195867
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral solution of misoprostol
Trial: 20691040
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (antibiotics, analgesics, and/or expectant management)
Trial: 18941533
Drug: Ortho All‐Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho All‐Flex Diaphragm, lubricant gel (Replens) and condoms
Trial: 18941533
Drug: Ortho All‐Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho All‐Flex Diaphragm, lubricant gel (Replens) and condoms with consistent use
Trial: 16963850
Drug: Anecortave acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave acetate 15 mg
Trial: 12652226
Drug: Anecortave acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave acetate (other doses)
Trial: 7457415
Drug: Diltiazem 120,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120, 180, and 240 mg/day
Trial: 6734694
Drug: metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 100 to 200 mg/day
Trial: 6734694
Drug: oxprenolol 120
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxprenolol 120 to 240 mg/day
Trial: 24426817
Drug: Zolpidem-ER 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem-ER 12.5 mg (bedtime dosing)
Trial: 24426817
Drug: Zaleplon 10
RxNorm normalized name: zaleplon 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon 10 mg (middle-of-the-night dosing)
Trial: 20003568
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g AXOS per day for 3 weeks
Trial: 12741433
Drug: Fluconazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (800 mg loading dose, 200 or 400 mg daily maintenance dose depending on renal function)
Trial: 11029368
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 400 microgram twice daily
Trial: 1576648
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 400 mg B.I.d for eight weeks
Trial: 30971593
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion at a dose of 2 μg/kg/h
Trial: 30971593
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at a dose of 0.1 μg/kg/min
Trial: 18690353
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and Aspirin
Trial: 28460140
Drug: L-T4 treatment
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-T4 treatment
Trial: 20636228
Drug: Sodium-restricted diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-restricted diet (2-3 g/day) and fluid restriction (1.5 L/day)
Trial: 18304952
Drug: Captopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (2 mg/kg/day, three doses a day)
Trial: 18304952
Drug: Nifedipine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (0.5 mg/kg/day, three doses a day)
Trial: 15677832
Drug: Medium-guidance group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-guidance group (MG; one supervised group session and two unsupervised home sessions per week, n = 16)
Trial: 11860948
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with HFRS vaccine
Trial: 8970471
Drug: Prophylactic HIV-1
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic HIV-1 vaccine
Trial: 1622173
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg orally every 8 h for the first 72 h and then every 12 h for a total of 10 days) plus a beta‐lactam agent plus an aminoglycoside
Trial: 1622173
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy of a beta‐lactam plus an aminoglycoside agent
Trial: 6519163
Drug: Propranolol 120
RxNorm normalized name: propranolol 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 120 mg orally
Trial: 28655079
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy only (CT)
Trial: 8857476
Drug: Poloxamer-188 infusion
RxNorm normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer-188 infusion for 48 hours
Trial: 8857476
Drug: Poloxamer-188 infusion
RxNorm normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer-188 infusion
Trial: 1346790
Drug: D1 agonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 agonist, piribedil, at 50‐100 mg/day, orally, for 8 weeks
Trial: 1346790
Drug: D2 agonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2 agonist, bromocriptine, at 2.5 ‐ 5 mg/day, orally, for another 8 weeks
Trial: 6206718
Drug: Transfusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion group (hemoglobin level kept above 10.0 g/dL)
Trial: 24231216
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg/d), tamsulosin (0.4 mg/d), saw palmetto (320 mg/d)
Trial: 24231216
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/d), saw palmetto (320 mg/d)
Trial: 18435852
Drug: Rosiglitazone added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone added to metformin
Trial: 22953318
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with family-based behavioural weight loss programme
Trial: 17538890
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PnCRM7)
Trial: 17538890
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen for those 7-11 months of age
Trial: 17538890
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen for those 12-23 months of age
Trial: 15037536
Drug: Infliximab (anti-TNF-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (anti-TNF-alpha therapy)
Trial: 15037536
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in combination with infliximab
Trial: 11813591
Drug: ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 250 mg q.i.d.
Trial: 11813591
Drug: ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 500 mg b.i.d.
Trial: 11813591
Drug: ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine bismuth citrate b.i.d. co-prescribed with clarithromycin 500 mg b.i.d. plus metronidazole 400 mg b.i.d.
Trial: 11813591
Drug: ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine bismuth citrate 400 mg b.i.d. for 14 days after initial treatment
Trial: 9726701
Drug: Jet injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injection of midazolam at doses of 100, 150, and 200 microg/kg
Trial: 9726701
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection of midazolam at a dose of 80 microg/kg
Trial: 9726701
Drug: Jet injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injection of midazolam at 200 microg/kg
Trial: 9726701
Drug: Jet injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injection of midazolam
Trial: 9726701
Drug: Jet injection
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injection and i.m. injection of midazolam
Trial: 9073056
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (A) 40 mg/m2 + Melphalan (M) 0.4 mg/kg + Cisplatin (C) 50 mg/m2
Trial: 9073056
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (A) 40 mg/m2 + Melphalan (M) 0.4 mg/kg
Trial: 26797134
Drug: Active beverage
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active beverage containing 361 mg of (poly)phenols and 120 mg of vitamin C, taken twice daily for 4 weeks
Trial: 24362012
Drug: Hydration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration group (increased water intake by 1.0-1.5 L/day for 6 weeks)
Trial: 21598839
Drug: Hypnosis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis with post-hypnotic suggestion
Trial: 19854321
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroids (prednisone 50-100 mg equivalent)
Trial: 19854321
Drug: Nontapered 5-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontapered 5- to 10-day course of corticosteroid therapy
Trial: 19854321
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of oral and inhaled corticosteroids
Trial: 19854321
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous corticosteroids, intramuscular and oral corticosteroid regimens
Trial: 19854321
Drug: Corticosteroid doses
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid doses greater than standard doses
Trial: 15568599
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (10 microg/kg/min for 72 hours)
Trial: 15568599
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (digitalis, diuretics, ACE-inhibitors)
Trial: 11737815
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (petrolatum)
Trial: 9357454
Drug: PTA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTA plus medical treatment
Trial: 9357454
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (control group)
Trial: 1337161
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (0.5 micrograms/day) for 8 weeks
Trial: 24398786
Drug: Freeze-dried powdered
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried powdered yacon (FDY) containing 7.4 g of FOS
Trial: 19846793
Drug: Metformin and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and/or Insulin
Trial: 17902730
Drug: 5% minoxidil
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% minoxidil applied twice daily
Trial: 17902730
Drug: Combined 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 5% minoxidil and 0.01% tretinoin applied once daily at night
Trial: 16234763
Drug: Nebivolol (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5-7.5 mg/day)
Trial: 16234763
Drug: Atenolol (75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (75-100 mg/day)
Trial: 10101621
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dynorphin A(1-13) (500 micrograms/kg)
Trial: 10101621
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dynorphin A(1-13) (120 micrograms/kg)
Trial: 7771420
Drug: Antireflux therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antireflux therapy (three types: two medical therapies and one surgical therapy)
Trial: 2342006
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 g intravenously with induction of anaesthesia)
Trial: 2342006
Drug: Piperacillin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (three doses of 2 g)
Trial: 6242956
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg mane
Trial: 6242956
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg nocte
Trial: 19355844
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitor (ChEI) treatment for 20 weeks
Trial: 14739496
Drug: roxithromycin (ROM)
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (ROM) 2x150 mg/day orally for 4 weeks
Trial: 14739496
Drug: placebo 2x1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2x1 tablet/day for 4 weeks